Oscar Health vs. UnitedHealth: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Oscar Health and UnitedHealth for 2026, highlighting Oscar’s 27.5% FY2025 revenue growth to $11.7 billion versus a $443.2 million net loss, while UnitedHealth generated $447.6 billion in revenue and $12.1 billion in net income. Oscar trades at 25.8x forward P/E and 0.5x P/S, while UnitedHealth trades at 20.6x forward P/E and 0.8x P/S. The piece is largely an investment opinion article, with limited new market-moving information beyond comparative fundamentals, risks, and valuation.

Analysis

The market is effectively pricing two different problems: OSCR is a duration bet on underwriting discipline scaling faster than regulatory volatility, while UNH is a de-risking trade on rerating from execution and reputational overhang. The subtle second-order point is that if ACA subsidies get extended or broadened, OSCR’s growth engine can accelerate disproportionately because incremental membership flows through a relatively fixed technology and distribution stack; if subsidies roll off, the downside is much steeper than headline revenue growth suggests because the book is concentrated in a single policy channel.

UNH’s larger issue is not size, it’s trust. In managed care, the market usually forgives modest margin pressure but punishes any perception that utilization management, claims practices, or cyber controls are impairing contract renewals; that creates a non-linear valuation discount that can persist for quarters even if earnings remain positive. At the same time, the balance-sheet and free-cash-flow profile give it optionality to buy back stock or absorb short-term noise, so this is more of a multiple-recovery story than a fundamental turnaround.

The contrarian angle is that OSCR may be less fragile than it looks if medical cost trends normalize, because its lower current valuation already embeds a lot of regulatory skepticism, while UNH may be less safe than it looks because its scale makes every misstep more visible and more litigable. The consensus treats UNH as the “safe” choice, but in a year where healthcare policy headlines can reset multiples quickly, the better risk/reward may come from owning the dislocation if you can tolerate volatility. That said, OSCR remains a binary execution story: a few basis points of medical margin variance can swing equity value materially over the next 12 months.

Key Decisions for Investors

• Long UNH / short OSCR as a one-year quality-vs-execution pair: use UNH as the lower-volatility leg and OSCR as the short only if you expect ACA policy noise or medical-cost volatility to reassert itself; target 15-20% relative return if risk appetite compresses.
• If taking a bullish view on the disruptor, buy OSCR on weakness only and size as a high-beta satellite position; thesis works best over 6-12 months if subsidy policy stays constructive and membership growth remains above premium growth.
• Own UNH as a core defensive healthcare holding, but consider trailing profit protection or covered calls for the next 2-3 quarters; the stock’s upside is likely more multiple expansion than earnings surprise, so upside capture may be capped near term.
• Watch for policy catalysts around ACA subsidies and CMS reimbursement into the next legislative window; if headlines turn supportive, add to OSCR first because the operating leverage to incremental enrollment is higher than the market implies.
• For tactical exposure, prefer call spreads over outright long OSCR if entering now: risk is asymmetric, and defined-risk upside participation is better than naked equity given the possibility of a sharp drawdown on adverse regulatory news.